GSK plc received UK regulatory approval on December 15, 2025, for Exdensur (depemokimab), a new treatment for asthma and chronic rhinosinusitis, showing a 54% reduction in asthma attacks in clinical trials.
AI Assistant
GSK PLC
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.